OmniAb, Inc. Common Stock (OABI) Stock
Key stats
- Market cap
- $743.89M
- Price / Earnings ratio
- -17.1x
- EPS (TTM)
- -$0.34
- Volume
- Loading
- 52-week high
- $5.45
- 52-week low
- $1.35
Source: third-party data provider, as of November 13, 2026
Compare with OABI
Recent news

OmniAb Q3 Earnings Call Highlights
OmniAb Q3 Earnings Call Highlights
OABI

OmniAb, Inc. (OABI) Reports Q3 Loss, Tops Revenue Estimates
OmniAb, Inc. (OABI) Reports Q3 Loss, Tops Revenue Estimates
OABI

OmniAb Reports Third Quarter 2026 Financial Results and Business Highlights
OmniAb Reports Third Quarter 2026 Financial Results and Business Highlights
OABI

OmniAb to Participate in Upcoming Investor Conferences in November
OmniAb to Participate in Upcoming Investor Conferences in November
OABI
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 54.75
- MACD 12/26/9
- 0.13
- EMA 9 of MACD
- 0.14
- MACD histogram
- -0.01
- SMA 50
- $4.74
- Price above SMA 50
- EMA 50
- $4.63
- Price above EMA 50
- SMA 200
- $2.83
- Price above SMA 200
- EMA 200
- $3.17
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 3 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

OmniAb Q3 Earnings Call Highlights
OmniAb Q3 Earnings Call Highlights
OABI

OmniAb, Inc. (OABI) Reports Q3 Loss, Tops Revenue Estimates
OmniAb, Inc. (OABI) Reports Q3 Loss, Tops Revenue Estimates
OABI

OmniAb Reports Third Quarter 2026 Financial Results and Business Highlights
OmniAb Reports Third Quarter 2026 Financial Results and Business Highlights
OABI

OmniAb to Participate in Upcoming Investor Conferences in November
OmniAb to Participate in Upcoming Investor Conferences in November
OABI

OmniAb Highlights $3B Milestone Pipeline, AI Antibody Platform at Conference
OmniAb Highlights $3B Milestone Pipeline, AI Antibody Platform at Conference
OABI

OmniAb to Report Third Quarter 2026 Financial Results on October 30
OmniAb to Report Third Quarter 2026 Financial Results on October 30
OABI

All You Need to Know About OmniAb, Inc. (OABI) Rating Upgrade to Buy
All You Need to Know About OmniAb, Inc. (OABI) Rating Upgrade to Buy
OABI

OmniAb Highlights Partner Pipeline, xPloration® Plans and Outlook, and Introduces the OmniTides™ Platform at Investor & Analyst Day
OmniAb Highlights Partner Pipeline, xPloration® Plans and Outlook, and Introduces the OmniTides™ Platform at Investor & Analyst Day
OABI

OmniAb to Host Investor & Analyst Day on October 6, 2026
OmniAb to Host Investor & Analyst Day on October 6, 2026
OABI

OmniAb to Participate in Upcoming Investor Conferences
OmniAb to Participate in Upcoming Investor Conferences
OABI
News tone: automated (AI) classification of the article's content, not a price prediction.
About OmniAb, Inc. Common Stock
OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Matthew W. Foehr | President, CEO & Director | 1973 |
| Mr. Kurt A. Gustafson | Executive VP of Finance & CFO | 1968 |
| Mr. Amechi Nwachuku | Executive VP & Chief Operating Officer | 1975 |
| Mr. Charles S. Berkman J.D. | Chief Legal Officer | 1969 |
| Ms. Cia McCaffrey | Senior Vice President of People & Talent | — |
| Dr. Bill Harriman Ph.D. | Senior Vice President of Discovery Partnership Mgt., Technology Development & Operations | — |
| Dr. Christel Iffland Ph.D. | Senior Vice President of R&D Portfolio Management and Technology Operations | — |
| Dr. Yasmina Noubia Abdiche Ph.D. | Senior Vice President of Exploratory Research | — |
| Dr. Bob Chen Ph.D. | Senior Vice President of Discovery Systems | — |
| Mr. Todd Pettingill C.F.A. | Vice President of Business Development & Strategy | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 54.75
- MACD 12/26/9
- 0.13
- EMA 9 of MACD
- 0.14
- MACD histogram
- -0.01
- SMA 50
- $4.74
- Price above SMA 50
- EMA 50
- $4.63
- Price above EMA 50
- SMA 200
- $2.83
- Price above SMA 200
- EMA 200
- $3.17
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
3 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $6.00
- Average
- $9.67
- High
- $12.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +62.7 | -5.7 | -17.2 | +123.5 | +11.7 | +2.4 | +0.2 |



